Background Safe and eff ective vaccines against Ebola could prevent or control outbreaks. The safe use of replicationcompetent vaccines requires a careful dose-selection process. We report the fi rst safety and immunogenicity results in volunteers receiving 3 × 10⁵ plaque-forming units (pfu) of the recombinant vesicular stomatitis virus-based candidate vaccine expressing the Zaire Ebola virus glycoprotein (rVSV-ZEBOV; low-dose vaccinees) compared with 59 volunteers who had received 1 ×10⁷ pfu (n=35) or 5 × 10⁷ pfu (n=16) of rVSV-ZEBOV (high-dose vaccinees) or placebo (n=8) before a safety-driven study hold.
Introduction
Despite unprecedented public health interventions, the Ebola virus disease (EVD) epidemic has infected more than 27 000 people, more than 11 000 of whom did not survive. 1 Safe and eff ective vaccines could prevent future outbreaks.
The live-attenuated recombinant vesicular stomatitis virus (rVSV) vaccine expressing the glycoprotein of Zaire Ebola virus (ZEBOV) was identifi ed as a promising candidate: 2 one injection of 1 × 10⁷ plaque-forming units (pfu) of rVSV-ZEBOV protected all (≥17) challenged nonhuman primates [3] [4] [5] [6] with no apparent safety concerns. 2, 5, 7, 8 After the Public Health Agency of Canada's donation of 800 vials of rVSV-ZEBOV to WHO, the latter created an African and European consortium (VEBCON [VSV-EBola CONsortium]) to initiate dose-escalation phase 1 trials of rVSV-ZEBOV in Germany (NCT02283099), Kenya (NCT02296983), and Gabon (PACT R2014000089322), as well as a double-blind phase 1/2 randomised, controlled trial in Geneva, Switzerland (NCT02287480). Preliminary results from these 9 and parallel US trials 10 indicate that rVSV-ZEBOV is immunogenic but reactogenic. In Geneva, 13 (25%) of 51 volunteers vaccinated with at least 1×10⁷ pfu had fever and 11 (22%) had oligoarthritis, the latter leading to a study hold. Meanwhile, preliminary data from Gabon suggested that lower vaccine doses might be better tolerated and remain immunogenic. 9 The Geneva trial thus resumed at the signifi cantly lower dose of 3 × 10⁵ pfu. Here, we report the fi rst safety and immunogenicity results in volunteers receiving 3 × 10⁵ pfu of rVSV-ZEBOV (low-dose vaccinees) compared with those receiving 1 × 10⁷ or 5 × 10⁷ pfu (high-dose vaccinees) before the study hold.
Methods

Study design and participants
In the Geneva rVSV-ZEBOV study, an investigatorinitiated phase 1/2, dose-fi nding, placebo-controlled, double-blind trial conducted at the University Hospitals of Geneva, Switzerland, we enrolled non-pregnant, immunocompetent and otherwise healthy adults aged 18-65 years. Additional inclusion and exclusion criteria are detailed at ClinicalTrials.gov (NCT02287480). All participants provided written informed consent. The study and all protocol amendments were reviewed and approved by the ethics committees of the Canton of Geneva and WHO as well as by the Swiss Agency for Therapeutic Products (Swissmedic).
Randomisation and masking
As previously described, 9 the fi rst 19 study participants formed a run-in group, receiving a single injection of 1×10⁷ pfu of rVSV-ZEBOV without blinding (open-label) under close clinical observation. Thereafter, participants planning to deploy to Ebola-aff ected regions (deployables) were randomly assigned (1:1) in a double-blind fashion to receive either single-injection 1 × 10⁷ pfu or 5 × 10⁷ pfu of vaccine, whereas non-deployables were randomly assigned (1:1:1) to receive either vaccine dose or placebo as a single injection. The emergence of arthritides in vaccinees prompted a study hold on Dec 9, 2014. 9 The trial resumed on Jan 5, 2015, to test the safety and immunogenicity of a sharply reduced dose; non-deployable participants were randomised (9:1) in double-blind fashion to a single injection of 3 × 10⁵ pfu or placebo, whereas deployable participants received single-injection 3 × 10⁵ pfu open-label (fi gure 1). The blind was intentionally lifted on April 7, 2015, for all high-dose volunteers (study day 84 [D84] visits completed) and for the 15 low-dose volunteers with vaccine-related arthritis, skin lesions, or both (D28 visits completed), and on May 18 for the remaining low-dose volunteers (D84 visits completed).
Procedures
The rVSV-ZEBOV candidate vaccine is replicationcompetent; the VSV vector's G gene was replaced by the glycoprotein gene of Zaire Ebola virus. 3 The vaccine (BPSC1001, lot number 003 0513) was manufactured at IDT Biologika (Dessau-Rosslau, Germany) and dispensed in single-dose vials as 1×10⁸ pfu per mL. The 3 × 10⁵ pfu in 0·5 mL dose was achieved by dilution with normal saline (appendix p 8). Placebo syringes containing 0·5 mL normal saline were packaged identically. Injections were given intramuscularly over 30 s into the deltoid.
Research in context
Evidence before this study The ClinicalTrials.gov database was searched on July 24, 2015, for studies including "Ebola" and "vaccine" as keywords. This search yielded 34 clinical trials using vaccines expressing the Ebola virus (EBOV) glycoprotein by recombinant vesicular stomatitis virus (rVSV-EBOV), chimpanzee adenovirus (ChAd3-EBO-Z), human adenovirus (Ad5-EBOV, Ad26-ZEBOV), or modifi ed vaccinia virus Ankara (MVA-BN Filo) vectored vaccines, DNA vaccines, or nanoparticles. The rVSV-ZEBOV vaccine is considered a promising candidate against Ebola virus disease; it has been selected for further phase 3 testing by WHO, the US Centers for Disease Control, the US National Institutes of Health, and the national health authorities of Guinea, Sierra Leone, and Liberia. Its safety and immunogenicity, however, require further defi nition. Two preliminary reports from a total of six phase 1 studies were recently published; these indicate that rVSV-ZEBOV is immunogenic, but reactogenic: vaccine viraemia was common and associated with frequent mild-to-moderate acute infl ammatory reactions and, in some vaccinees, with viral dissemination leading to arthritis and occasional dermatitis.
Added value of this study
This study shows that a signifi cant rVSV-ZEBOV dose reduction from 1-5 × 10⁷ to 3 × 10⁵ pfu successfully decreases the occurrence and magnitude of viraemia, monocyte activation, and early reactogenicity. This dose reduction, however, negatively aff ects antibody responses, fails to prevent viral seeding of peripheral tissues, and thus does not decrease the risk of vaccine-induced arthritis, dermatitis, and cutaneous vasculitis.
Implications of all the available evidence
These results suggest that reducing the dose of rVSV-ZEBOV is not a useful strategy to prevent vaccine-induced arthritis, dermatitis, or vasculitis. Like its effi cacy, the safety of rVSV-ZEBOV needs further defi nition in the target populations of Africa.
See Online for appendix
Clinical and laboratory assessments were done at baseline and on days 1, 3, 7, 14, and 28 after injection. Participants were given a diary for the fi rst 2 weeks and asked to record all adverse events, both solicited (prompted in the diary and by investigators at study visits) and unsolicited. Solicited adverse events were local pain, swelling and erythema, chills, myalgia, subjective and objective fever, loss of appetite, headache, and fatigue; after the study hold, arthralgia and skin lesions were added as solicited events for low-dose vaccinees. Adverse events occurring early (≤7 days after injection) are referred to as reactogenicity and do not include arthritis, dermatitis, and vasculitis. Severity was assessed according to US Food and Drug Administration toxicity scales: 11 mild symptoms not interfering with usual activity are grade 1, moderate symptoms leading to some interference with activity are grade 2, and major symptoms preventing usual activity are grade 3.
Laboratory analyses included full blood count, creatinine, and liver function tests. Adverse events were listed per participant and are reported individually and in aggregate. All participants with swollen joint involvement were referred to a rheumatologist (AF) and all but two underwent ultrasound imaging. Arthritis was confi rmed if the study team noted swelling or if imaging showed joint eff usion(s), or both. Participants with skin lesions underwent biopsy sampling, swabbing, or puncture of lesions, as appropriate.
Detection of rVSV RNA was done by a quantitative RT-PCR assay targeting the nucleoprotein gene of VSV-Indiana, as previously described. 9 RT-PCR was done on days 1, 3, and 7 post injection on all plasma specimens (limit of detection: 30 copies per mL), and occasionally on swabs of oral or skin lesions or on synovial fl uid, or both.
Fresh whole blood was treated with lysis buff er to remove erythrocytes and 1-2 × 10⁶ cells were stained with a panel of monoclonal antibodies including against the CD169 monocyte activation marker 12, 13 before data acquisition by fl ow cytometry (appendix p 8). Monocyte activation was characterised by the geometric mean fl uorescence intensity ratio compared with isotype control. Sera were assessed on days 0 and 28 after injection. ELISA for EBOV-glycoprotein-specifi c antibodies used the homologous Zaire-Kikwit strain glycoprotein following the US Army Medical Research Institute for Infectious Diseases' (USAMRIID) standard operating procedure (SOP AP-03-35-00; USAMRIID ELISA) or inactivated whole virions of the Zaire-Makona strain, as described. 9 EBOV glyocprotein-specifi c antibodies were also assessed by endpoint dilutions with a commercial ELISA assay (Alpha Diagnostic, TX, USA; ADI ELISA), according to the manufacturer's instructions (quantifi cation method C, appendix p 9). The relative amounts of EBOV-glycoprotein-specifi c antibodies were reported as endpoint titres or the geometric mean (logarithm base 10) titres (GMT) or concentrations (GMC) of arbitrary ELISA units per mL with 95% CIs, as indicated. Neutralising antibodies (NTAb) were detected with rVSV pseudovirions expressing the luciferase reporter gene complemented by glycoprotein from the ZEBOV 95 Kikwit strain, as described. 9
Outcomes
Primary safety and immunogenicity outcome measures are the incidence of adverse events within 14 days and quantitative EBOV-specifi c IgG antibody responses measured by ELISA across dose groups on day 28, respectively. The incidence of adverse events occurring more than 14 days after intervention and cellular and humoral immunogenicity of rVSV-ZEBOV across dose groups are assessed secondarily.
Statistical analysis
The combined target sample size for all VEBCON studies was roughly 250 participants, because WHO estimates had concluded that roughly 74-124 participants would be needed in each dose arm to show a greater than twofold diff erence in EBOV glycoprotein-specifi c antibody titres. The Geneva proportion of roughly 115 volunteers was based primarily on recruitment capacity. At the time of the study hold, 59 of the 115 participants had been included, thus 56 inclusions were scheduled upon study resumption.
Comparisons between groups were done with χ² or Fisher's exact tests or by Mann-Whitney or Kruskal-Wallis tests for continuous factors for independent groups; McNemar and Wilcoxon tests were used for measures repeated over time. Unadjusted associations between predefi ned factors and the most common adverse events were tested. Associations between age and dose and arthritis risk were assessed with a logistic regression model with an interaction term between age and dose. Antibody responses are reported as GMT or GMC with 95% CIs and are represented by reverse cumulative distributions (RCD). Antibody response patterns across doses were assessed with Cuzick's test for trend. 14 Associations with antibody titres were assessed by means of linear regression models in the low-dose group (unadjusted associations) and in all vaccinees (associations adjusted for vaccine dose). Because the distributions of antibody titres were skewed, a logarithm transformation (base 10) was applied and associations were expressed as ratios of geometric means. Correlations between assays were assessed (Spearman's coeffi cient). All statistical tests were twosided with an α risk of 0·05.
In the absence of relevant diff erences in baseline characteristics and safety outcomes between recipients of 1 × 10⁷ and 5 × 10⁷ pfu (high-dose participants), 9 between placebo recipients from both groups, and between randomised and open-label recipients of a given vaccine dose (table 1; appendix pp 12-13), their respective results are presented together.
Role of the funding source
The funder (the Wellcome Trust Foundation) had no role in the study design, data collection, data analysis or data interpretation, or writing of the report. The corresponding author had full access to all study data and had fi nal responsibility for the decision to submit for publication.
All
Intervention groups 
Data are n (%) or mean (SD). pfu=plaque-forming units. AST=aspartate aminotransferase. ALT=alanine aminotransferase. *As previously described. 9 †Placebo recipients from both dose groups did not diff er signifi cantly (appendix p 13) and were pooled. ‡Data missing for one participant. 
Results
The trial is ongoing with a follow-up period of 12 months; all reported results are from interim databases.
At the time of the study hold between Dec 9, 2014, and Jan 5, 2015, 59 high-dose participants had received rVSV-ZEBOV at 1×10⁷ pfu (n=35) or 5 × 10⁷ pfu (n=16) or placebo (n=8). 9 After trial resumption, 43 non-deployable participants were randomly assigned (9:1) to receive low-dose rVSV-ZEBOV (3 × 10⁵ pfu) or placebo in double-blind fashion, while 13 deployable participants received 3×10 5 pfu open-label (fi gure 1). Altogether, in the low-dose group 51 participants received rVSV-ZEBOV and fi ve received placebo. Median age was 40 years (IQR 30-50, range 20-63). Like high-dose participants, all low-dose participants have been followed up for at least 12 weeks (median 96 days, range 83-104). Baseline characteristics of low-dose vaccinees were similar to those of placebo recipients and high-dose vaccinees 9 (table 1; appendix pp 12-13).
There were no serious adverse events. In the fi rst 14 days post injection, solicited reactogenicity, unsolicited events (median three events [IQR 2-6; range 0-13] per participant), or both were noted in 45 (88%) of low-dose vaccinees (fi gure 2; appendix pp 14-15) compared with 50 (98%) of 51 high-dose vaccinees and two (15%) of 13 placebo recipients (p=0·141). 9 Most events were mild or moderate: their incidence and intensity did not diff er signifi cantly between low-dose vaccinees and placebo recipients. Local pain (11 [22%] ) were signifi cantly less common (p<0·0001 for pain, p=0·001 for subjective and objective fever, and p=0·004 for myalgia) and less intense (fi gure 2; appendix p 14) in low-dose vaccinees than in high-dose vaccinees. Grade 3 symptoms were reported by slightly fewer low-dose vaccinees than highdose vaccinees (seven [14%] of 51 vs 11 [22%] of 51, not signifi cant; p=0·28]. The onset of reactogenicity was signifi cantly later in low-dose vaccinees than in high-dose vaccinees: 25 (19%) of 133 vs 12 (5%) of 248 solicited adverse events with onset ≤7 days after injection began after day 2 (p<0·0001; appendix p 16). Duration of reactogenicity was similarly short (median 1 day, IQR <24 h-3 days). Reactogenicity was not aff ected by age or sex (data not shown).
Between days 1 and 3 after injection, lymphocyte, neutrophil, and platelet counts decreased in low-dose vaccinees compared with high-dose vaccinees, whereas monocytes increased (appendix pp [17] [18] . The decline in circulating lymphocytes, neutrophils, and platelets occurred on the same days, but was signifi cantly milder in low-dose versus high-dose vaccinees (appendix p 19). Monocytosis was associated with increased expression of the CD169 monocyte-activation marker 12 on classical, intermediate, and non-classical blood monocytes 15 from a random subset of 46 parti cipants (appendix p 20). The intensity of CD169 expression was signifi cantly weaker in low-dose versus high-dose vaccinees, suggesting a dose eff ect on monocyte activation. Liver profi les and creatinine levels remained unchanged (data not shown).
Following rVSV-ZEBOV RNA quantifi cation by RT-PCR, only ten (20%) of 51 low-dose vaccinees had detectable RNA levels at any time compared with 46 (90%) of 51 high-dose vaccinees (p<0·0001; appendix pp [21] [22] . When detected, viraemia was minimal and signifi cantly reduced (p<0·0001) among low-dose vaccinees. No correlation was noted between viraemia occurrence or peak value and age, sex, lymphopaenia, and adverse event frequency or intensity.
Serum antibodies induced by rVSV-ZEBOV were assessed using four distinct assays. Baseline antibodies, occasionally detected above quantifi cation thresholds, increased to signifi cantly higher titres after immunisation (fi gure 3; appendix pp [23] [24] [25] [26] [27] ; table 3 ). Therapeutic arthrocentesis with lidocaine and betamethasone or triamcinolone infi ltration was required in three of 13 participants. Functional impact remained moderate, with a median score of 2·7 (IQR 1·0-3·7) on the Routine Assessment of Patient Index Data (RAPID3). 16 PCR detected rVSV in the synovial fl uid of two of three participants assessed, at 1337 and 5000 copies per mL, respectively. rVSV viraemia remained negative in all participants at diagnosis and at all times in ten (76%) of 13 participants. No association of arthritis with sex or reactogenicity was noted. The median age of participants with arthritis (51·8 years [IQR 47·3-54·0]) was signifi cantly higher than that of vaccinees without arthritis (36·7 [29·7-42·7; p=0·006]). In a logistic regression model including high-dose and low-dose vaccinees, age was signifi cantly associated with the risk of arthritis in low-dose vaccinees (odds ratio [OR] 2·43 [95% CI 1·24-4·78; p=0·010] per 10 additional years), but not in high-dose vaccinees (OR 0·76 per 10 additional years [95% CI 0·43-1·35], p=0·356; appendix pp 31-32). The two ORs were signifi cantly diff erent (p=0·011), identifying an association between age and arthritis only in low-dose vaccinees.
In the second and third weeks after immunisation, seven (54%) of 13 low-dose vaccinees with arthritis developed the maculopapular (n=5) and/or vesicular (n=4) dermatitis previously described in three (27%) of 11 high-dose vaccinees with arthritis. 9 In addition, two vaccinees presented with purpura on the lower legs. The fi rst is a 55-year-old man with onset of arthralgia on day 14 (table 3; case number 4). On day 17, a painless, non-palpable petechial and purpuric rash (10 cm × 4 cm) was noted on his left leg (fi gure 4A). Histological examination showed a dense CD4+ T-cell lymphocytic infi ltrate surrounding dermal blood vessels with swollen endothelial cells and extravasated erythrocytes, consistent with lymphocytic vasculitis (fi gure 4B, C). 17 A deep dermal swab taken during skin biopsy confi rmed the presence of rVSV RNA. The second participant is a 48-year-old woman who developed a painless, pruritic, non-palpable petechial and purpuric rash of both lower legs (fi gure 4D) on day 12, with a macular rash on both arms and a papule on one fi nger, but no arthritis. A skin biopsy of a purpuric lesion showed similar alterations (fi gure 4E, F), leading to the same diagnosis of cutaneous lymphocytic vasculitis. A swab at the biopsy site remained negative for rVSV-ZEBOV. Platelet counts, urinalysis, and creatinine levels were within normal limits in both participants. The clinical course was favourable for both, with spontaneous resolution of the vasculitis after 14 days and 10 days, respectively. 
EBOV-GP ELISA ADI (EU per mL)
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Discussion
High-dose rVSV-ZEBOV vaccination led to detectable viraemia in almost all vaccinees and viral dissemination with secondary arthritis in up to 22% of Geneva vaccinees. 9 Here, we show that a major dose reduction substantially decreased viraemia and reactogenicity, but did not preclude the viral dissemination to joints and skin leading to arthritis, dermatitis, and vasculitis. Neither of these observations was anticipated.
Replicating vaccines classically remain infectious and thus trigger similar vaccine-specifi c reactogenicity across a large dose range. Reduction of the 17D yellow-fever vaccine dose from 2000 pfu to 20 pfu did not change its reactogenicity, 18 and adverse reactions to a live-attenuated dengue virus type 4 candidate remained unchanged between 1 × 10⁵ pfu and 1 pfu. 19 The same was expected for rVSV-ZEBOV: reduction of its dose from 2000 pfu to 2 pfu did not reduce its effi cacy in mice, 8 and reactogenicity and viraemia have been similar in human beings receiving doses between 3 × 10⁶ pfu and 5 × 10⁷ pfu. 9, 10 Weaker reactogenicity was noted in 20 Gabonese participants immunised with 3 × 10⁵ pfu; 9 this could have refl ected diff erences in baseline immunity, 20 study populations, or both. Our fi ndings now show a strong dose eff ect of rVSV-ZEBOV on acute reactogenicity: at 3 × 10⁵ pfu, early reactogenicity was similarly low in vaccinees and placebo recipients and signifi cantly stronger in high-dose vaccinees (fi gure 2).
A rVSV-ZEBOV dose reduction to 3 × 10⁵ pfu also reduced the occurrence and magnitude of viraemia, . This fi nding again contrasts with the 17D yellow-fever vaccine: reduction of the dose delayed the onset of viraemia, which lasted longer and reached higher levels-an eff ect presumed to refl ect the induction of weaker innate responses and thus protracted viral replication. 18 Whether resulting from direct infection or indirect activation, both of which are currently indistinguishable, monocyte activation (defi ned by CD169 expression) was indeed reduced in low-dose vaccinees, and the onset of acute reactogenicity was signifi cantly delayed. Thus, the replication pattern of the rVSV-ZEBOV-vector vaccine diff ers from that of live-attenuated vaccines. In-depth analyses of innate responses will be needed to unravel the correlations between rVSV-ZEBOV dose, viraemia, and viral replication in the periphery, immune activation, and the onset of infl ammatory symptoms. The data also show a dose eff ect on the immunogenicity of rVSV-ZEBOV. Titres of EBOV-glycoprotein-binding and neutralising antibodies were signifi cantly weaker in lowdose recipients, aff ecting the seropositivity rates of the less sensitive assays. Their distribution (fi gure 3E, F) was remarkably similar to that noted in the 20 Gabonese recipients of 3 × 10⁵ pfu, 9 suggesting a dose rather than a population eff ect on immunogenicity. Until correlates of protection against EBOV are established, any prediction as to whether this reduction in antibody titres would have a detrimental eff ect on protection remains speculative. Assay sensitivities vary substantially, and correlations between antibody titres elicited in rVSV-ZEBOVimmunised non-human primates and human beings have not yet been established. Similarly, direct correlations between immune responses elicited in humans by rVSV-ZEBOV and the chimpanzee adenovirus 3 (ChAd3)vectored vaccine 21 are yet lacking. At high doses (≥1 × 10⁷ pfu and 1 × 10¹¹ pfu, respectively), both vaccines seem to elicit initial EBOV-glycoprotein-specifi c responses of a similar magnitude. An advantage of rVSV-ZEBOV, which contributed to its selection for further trials in west Africa, is its anticipated potential as a single-dose vaccine.
The decision to resume the trial at 3 × 10⁵ pfu was motivated by the hope that a substantial dose reduction would obviate the viral dissemination leading to arthritis and dermatitis, neither of which had been reported at 3 × 10⁵ pfu. 9 Yet rVSV-ZEBOV remained equally arthritogenic, with the recovery of vaccine RNA in synovial fl uid (in this paper and a previous report 9 ) confi rming viral arthritis.
This study adds important information. First, arthritis is not dose dependent, but intrinsic to rVSV-ZEBOV. Arthritis has not been reported after wild-type VSV infection [22] [23] [24] [25] [26] or vaccination with rVSV with non-EBOVglycoprotein inserts, 27 whereas polyarthralgia is frequent after Ebola virus disease, 28 suggesting immune reactions to EBOV antigens in rVSV-ZEBOV infected joints. Arthritis was not reported after immunisation with the replicationdefi cient ChAd3-ZEBOV vaccine expressing the same glycoprotein, 21 suggesting the pathophysiological role of viral replication. Second, viraemia was never detected in ten of 13 low-dose participants with arthritis, refl ecting the capacity of rVSV-ZEBOV to target the joints even when replication in the blood is apparently limited. Our current hypothesis is that the highly expressed 29 EBOV-glycoprotein mediates the entry of rVSV-ZEBOV into blood monocytes, 30 which transport rVSV-ZEBOV to the joints, where replication occurs and local infl ammation is triggered, persisting until viral antigens are eventually cleared by the immune system. Whether vaccine-induced arthritis might be obviated by further attenuation of the rVSV backbone or modifi cation of the EBOV-glycoprotein, or both, is unknown. Third, arthritis was associated with dermatitis in more than 50% of low-dose vaccinees with arthritis. Further analyses will determine whether this results from the weaker innate responses facilitating viral dissemination to peripheral tissues, delayed viral clearance, or both. Finally, a signifi cant age eff ect was observed: low-dose vaccinees with arthritis were signifi cantly older, as previously reported for rubella vaccine-induced arthritis: 31, 32 the relative risk of arthritis increased from 5% at 20 years to 60% at 60 years (appendix p 32). This association was not noted in high-dose vaccinees. Further investigation is required to determine whether young age exerts a protective eff ect through faster viral clearance in peripheral tissues or attenuated infl ammatory joint responses, or both, at low-but not high-doses, and whether joints become more vulnerable to viral seeding by infected infl ammatory cells with age, increasing viral load, or both. Regardless of the mechanism, the determinants of rVSV-ZEBOV-induced oligoarthritis thus include host factors. One case of arthritis has been reported from Africa 9 and cases of transient low-grade oligoarthritis and skin lesions have now been identifi ed (but at lower frequency) in a US multicentre trial (Merck/NewLink, personal communication). Thus, the frequency of vaccine-related arthritis, dermatitis, and vasculitis remains higher in the Geneva population than in other sites. Potential contributing factors include diff erences in reporting or clinical investigative approaches; because these events are generally mild or moderate, and not readily attributed to vaccination, they could escape notifi cation. Host factors regulating infl ammatory or immune responses probably diff er between study populations and include age, sex, fi tness and physical activity, body-mass index, baseline immunity, and human leucocyte antigen types. Their relative contributions could aff ect the frequency and severity of arthritis, requiring safety evaluation in the target populations of Africa. The occurrence of rVSV-ZEBOV-associated lymphocytic vasculitis was unexpected, as it also does not occur in wild-type VSV infection. Purpuric areas were free of dermatitis and lymphocytic infi ltration was perivascular, absent from the dermoepidermal junction (as observed in rVSV-ZEBOV-induced dermatitis 9 ), but concentrated around swollen endothelial cells. 17 These clinical and histological patterns are reminiscent of the so-called gloves-and-socks syndrome caused by parvovirus B19, 33 which results from the infection of endothelial cells in dermal capillaries. 34 This suggests that rVSV-ZEBOV might target and infect dermal endothelial cells, possibly mediated by EBOV-glycoprotein in view of its noted eff ects on endothelial cells. 35 The delayed onset of purpura, not associated with early or delayed viraemia, and the perivascular CD4+ T-cell infi ltrate suggest a pathophysiological role for vaccine-induced T cells.
This study has limitations. It had to include open-label immunisations to meet the request of international agencies not to impose placebo on deployable individuals, and was interrupted by a safety-driven study hold. Thus, participants were not simultaneously randomised to lowdose or high-dose vaccine, but injected before or after a 3-week study hold; nonetheless, we identifi ed no relevant disparities in baseline characteristics that could explain the diff erent outcomes observed. Sample size was largely based on logistic capacities, such that the study was not powered to examine modest specifi c correlations. Thus, the absence of association does not exclude its existence. Information about the fi rst arthritis cases was disseminated to all volunteers, thus an awareness bias cannot be excluded. However, arthritis, dermatitis, and vasculitis were confi rmed by objective fi ndings in all participants.
The rVSV-ZEBOV vaccine was selected for further phase 3 testing in Guinea, Sierra Leone, and Liberia. Its safety and effi cacy require further defi nition in these target populations. As low-grade, transient symptoms would not aff ect the use of an eff ective Ebola vaccine, the further characterisation of frequency and severity of arthritis-related, dermatitis-related, or vasculitis-related symptoms (or sequelae, if any) in African populations will critically inform the development of rVSV-ZEBOV.
The study provides a fi rst opportunity to directly compare the eff ects of various doses of rVSV-ZEBOV. This dose eff ect is strong: reduction of the dose of rVSV-ZEBOV from 10⁷ pfu or greater to 3 × 10⁵ pfu substantially reduced viraemia and acute reactogenicity, but it negatively impacted antibody responses and did not prevent the homing of rVSV-ZEBOV towards the joints, skin, and endothelium. These fi ndings do not support a strategy of rVSV-ZEBOV dose reduction to prevent vaccine-induced arthritis, dermatitis, or vasculitis.
